
Intra-Cellular Therapies ITCI
Annual report 2024
added 02-21-2025
Intra-Cellular Therapies General and Administrative Expenses 2011-2026 | ITCI
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 504 M | 410 M | 359 M | 273 M | 186 M | 64.9 M | 30.1 M | 23.7 M | 24.8 M | 18.2 M | 10.3 M | - | 4.03 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 504 M | 4.03 M | 159 M |
Quarterly General and Administrative Expenses Intra-Cellular Therapies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 M | 122 M | 113 M | - | 105 M | 101 M | 98.9 M | - | 88.4 M | 100 M | 75.5 M | - | 70.5 M | 69.9 M | 52.6 M | - | 52.5 M | 41.4 M | 34.1 M | - | 15 M | 15.4 M | 11.7 M | - | 7.97 M | 6.73 M | 6.38 M | - | 5.32 M | 6.25 M | 6.31 M | - | 6.27 M | 6.47 M | 5.06 M | - | 3.89 M | 3.99 M | 3.77 M | - | 2.58 M | 2.12 M | 1.91 M | - | 1.3 M | 903 K | 1.05 M | - | 802 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 802 K | 37.3 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.5 | 0.45 % | $ 862 M | ||
|
ADC Therapeutics SA
ADCT
|
71.5 M | $ 3.83 | 1.32 % | $ 105 M | ||
|
Agenus
AGEN
|
54.4 M | $ 3.64 | 9.31 % | $ 108 M | ||
|
Agios Pharmaceuticals
AGIO
|
180 M | $ 35.08 | -0.36 % | $ 2.03 B | ||
|
Akebia Therapeutics
AKBA
|
107 M | $ 1.39 | 0.36 % | $ 357 M | ||
|
Akari Therapeutics, Plc
AKTX
|
9.28 M | $ 3.95 | -11.63 % | $ 266 B | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Aldeyra Therapeutics
ALDX
|
9.6 M | $ 1.57 | -5.42 % | $ 94.3 M | ||
|
Aligos Therapeutics
ALGS
|
20.7 M | $ 8.08 | 1.38 % | $ 79.9 M | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 331.14 | 3.85 % | $ 43.4 B | ||
|
Altimmune
ALT
|
28.1 M | $ 3.4 | 1.8 % | $ 300 M | ||
|
ALX Oncology Holdings
ALXO
|
23.8 M | $ 1.99 | 0.81 % | $ 107 M | ||
|
Amgen
AMGN
|
7.05 B | $ 344.03 | -1.12 % | $ 185 B | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Amneal Pharmaceuticals
AMRX
|
527 M | $ 12.27 | -1.68 % | $ 3.85 B | ||
|
Anika Therapeutics
ANIK
|
95.8 M | $ 14.99 | 1.28 % | $ 220 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
ANI Pharmaceuticals
ANIP
|
250 M | $ 73.8 | -0.55 % | $ 1.43 B | ||
|
Annexon
ANNX
|
31.7 M | $ 5.56 | 1.0 % | $ 862 M | ||
|
Annovis Bio
ANVS
|
4.48 M | $ 2.56 | 12.28 % | $ 52.6 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.88 | -5.16 % | $ 4.8 M | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Aprea Therapeutics
APRE
|
6.48 M | $ 0.7 | -1.87 % | $ 4.58 M | ||
|
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.12 | -0.24 % | $ 441 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 8.14 | 1.31 % | $ 223 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Ardelyx
ARDX
|
337 M | $ 5.99 | 0.84 % | $ 1.44 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
argenx SE
ARGX
|
308 M | $ 749.99 | 0.48 % | $ 25 B | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 24.06 | 1.82 % | $ 3.06 B | ||
|
Arvinas
ARVN
|
95.9 M | $ 10.87 | 0.14 % | $ 771 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
124 M | $ 60.28 | -1.23 % | $ 8.06 B | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Assembly Biosciences
ASMB
|
19.6 M | $ 29.51 | 1.72 % | $ 331 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.62 | 1.82 % | $ 8.71 B |